JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosis-Reference-Cited by-同舟云学术

JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosis

Published:2012-08-27 Issue:9 Volume:64 Page:3006-3015
ISSN:0004-3591
Container-title:Arthritis & Rheumatism
language:en
Short-container-title:Arthritis & Rheumatism

Author:

Dees Clara,Tomcik Michal,Palumbo-Zerr Katrin,Distler Alfiya,Beyer Christian,Lang Veronika,Horn Angelika,Zerr Pawel,Zwerina Jochen,Gelse Kolja,Distler Oliver,Schett Georg,Distler Jörg H. W.

Publisher

Wiley

Subject

Pharmacology (medical),Immunology,Rheumatology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/art.34500/fullpdf

Reference33 articles.

1. Scleroderma;Gabrielli;N Engl J Med,2009

2. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database;Tyndall;Ann Rheum Dis,2010

3. Systemic sclerosis: a prototypic multisystem fibrotic disorder;Varga;J Clin Invest,2007

4. The Janus kinases (Jaks);Yamaoka;Genome Biol,2004

5. Hematopoietic cytokine receptor signaling;Baker;Oncogene,2007

Cited by 124 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. JAK2 inhibitors improve RA combined with pulmonary fibrosis in rats by downregulating SMAD3 phosphorylation;International Journal of Rheumatic Diseases;2024-05

2. Assessment of serum and cutaneous JAK3 in juvenile scleroderma;The Egyptian Journal of Pediatric Allergy and Immunology;2024-04-01

3. MicroRNA-21a-5p inhibition alleviates systemic sclerosis by targeting STAT3 signaling;Journal of Translational Medicine;2024-04-01

4. S2k‐Leitlinie: Diagnostik und Therapie der zirkumskripten Sklerodermie;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2024-04

5. Skin and lung fibrosis induced by bleomycin in mice: a systematic review;Reumatismo;2024-03-22